Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.90
-0.19 (-2.35%)
Mar 3, 2026, 4:00 PM EST - Market closed
Journey Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Journey Medical stock have an average target of 12.67, with a low estimate of 12 and a high estimate of 13. The average target predicts an increase of 60.38% from the current stock price of 7.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 25, 2025.
Analyst Ratings
The average analyst rating for Journey Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +64.56% | Aug 25, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $9 → $13 | Strong Buy | Maintains | $9 → $13 | +64.56% | Aug 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +51.90% | Jul 30, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +13.92% | Sep 6, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +39.24% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
65.95M
from 56.13M
Increased by 17.48%
Revenue Next Year
102.76M
from 65.95M
Increased by 55.83%
EPS This Year
-0.49
from -0.72
EPS Next Year
0.26
from -0.49
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 68.9M | 110.4M | |
| Avg | 65.9M | 102.8M | |
| Low | 62.8M | 96.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 22.7% | 67.4% | |
| Avg | 17.5% | 55.8% | |
| Low | 11.9% | 46.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.45 | 0.38 | |
| Avg | -0.49 | 0.26 | |
| Low | -0.52 | 0.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.